India's pharmaceutical manufacturers are offering treatments at globally unmatched prices, reducing costs by approximately 70%. This comes after the Indian patent for semaglutide expired. Major players are now planning launches in Canada, Brazil, Latin America, and Turkey to capture a portion of the global obesity market, which is expected to reach $100 billion by the end of the decade. Sun Pharmaceutical Industries, India's largest drugmaker, debuted its injectable semagledide under the brand Noveltreat for weight management and Sematrinity for Type 2 diabetes. Dr. Reddy's Laboratories (NYSE:RDY) launched its version, Obeda, in a disposable pen format, with monthly injectables starting at $42.59.